Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects.
about
Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditionsStatistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticlesDevelopment and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design.QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes.Systematic optimization of human pluripotent stem cells media using Design of Experiments.QbD-oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid-liquid extraction and chromatographic separation.Optimization, in vitro cytotoxicity and penetration capability of deformable nanovesicles of paclitaxel for dermal chemotherapy in Kaposi sarcoma.Optimization of Salbutamol Sulfate Dissolution from Sustained Release Matrix Formulations Using an Artificial Neural NetworkPolymers in small-interfering RNA deliveryDeveloping oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects.Design of pressure-driven microfluidic networks using electric circuit analogy.Design of experiments (DoE) in pharmaceutical development.Long-chain triglycerides-based self-nanoemulsifying oily formulations (SNEOFs) of darunavir with improved lymphatic targeting potential.Design and evaluation of a metronidazole central core matrix tablet.Plantago ovata F. Mucilage-Alginate Mucoadhesive Beads for Controlled Release of Glibenclamide: Development, Optimization, and In Vitro-In Vivo Evaluation.Formulation and optimization of sustained release tablets of venlafaxine resinates using response surface methodology.Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration.QbD-Enabled Development of Novel Stimuli-Responsive Gastroretentive Systems of Acyclovir for Improved Patient Compliance and Biopharmaceutical Performance.Systematic development of optimized SNEDDS of artemether with improved biopharmaceutical and antimalarial potential.Modelling of aflatoxin G1 reduction by kefir grain using response surface methodologyFormulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride.Formulation of a dry powder influenza vaccine for nasal delivery.Systematic Development and Validation of a Thin-Layer Densitometric Bioanalytical Method for Estimation of Mangiferin Employing Analytical Quality by Design (AQbD) Approach.Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers.Combined Effect of Synthetic and Natural Polymers in Preparation of Cetirizine Hydrochloride Oral Disintegrating Tablets: Optimization by Central Composite DesignDevelopment of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eyeDeveloping micro-/nanoparticulate drug delivery systems using "design of experiments".QbD-Driven Development and Validation of a Bioanalytical LC-MS Method for Quantification of Fluoxetine in Human Plasma.Formulation and mathematical optimization of controlled release calcium alginate micro pellets of frusemide.A distribution-free multi-factorial profiler for harvesting information from high-density screenings.Nomogram for computing the value of similarity factor.In vitro and preclinical assessment of factorial design based nanoethosomes transgel formulation of an opioid analgesic.Convolution and validation of in vitro-in vivo correlation of water-insoluble sustained-release drug (domperidone) by first-order pharmacokinetic one-compartmental model fitting equation.Optimization and validation of a HPLC method for simultaneous determination of aflatoxin B1, B2, G1, G2, ochratoxin A and zearalenone using an experimental design.Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation.Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics.Matrix-type transdermal films to enhance simvastatin ex vivo skin permeability.Development, optimization, and in vitro characterization of dasatinib-loaded PEG functionalized chitosan capped gold nanoparticles using Box-Behnken experimental design.Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance.Biocompatible lidocaine and prilocaine loaded-nanoemulsion system for enhanced percutaneous absorption: QbD-based optimisation, dermatokinetics and in vivo evaluation.
P2860
Q28482479-E25F1F1A-93FC-4EED-B23B-D4221B869F70Q33681176-848602FA-9948-47BD-B917-0FD5BE76A9C2Q34784654-AC5EDC34-02ED-4C11-BB46-304A271D5F1AQ35208156-724043DD-40C8-4787-967A-50303F724CADQ35568999-CF41E6E1-7BB7-4E25-8644-797341D3D599Q35767808-6D57F027-98B2-4325-ACB3-58342CF0D393Q35770551-C412C0FA-5633-4A62-95BC-9309735D6836Q37702753-F90A23AE-4299-4D8A-805B-49E42146C361Q37900314-1C2A7123-9DAC-4B5B-BACC-18F0B8B45135Q37905839-03FADFFC-3A1A-46B5-A30A-D5C920D8CF2DQ37969625-4BB313B7-D47D-4889-9146-339934ECABF3Q38976314-834A8D6C-E1B1-4101-821C-FD1F803F8896Q40084144-7E7DCB16-8777-4F33-9F16-6A598CDC84DAQ40302835-87528B7D-816C-44B5-A216-ED1F5AF9F605Q40335982-82167133-C7E4-470B-B1D0-55843A58781EQ40406953-17ECF60C-F99E-4089-A430-95A8F831FABCQ40584239-EEB2E7FA-1FA4-48BA-8AAD-1804A060803FQ40664575-A714074A-FCDC-4C13-B1EE-40EAAB56C858Q40737520-0F24ECF4-49E3-43C9-96BB-C9AA8A09D41FQ41168668-CE0585C6-0BCC-4695-8248-6E90B436F693Q41182114-3ACAF9AF-9271-41FD-BC44-294F2B53B01CQ41823469-A611B807-2344-4FFA-97B5-4D3AE83DDFBFQ41961901-4E4568C7-F316-47F3-9195-57CE871DBBC0Q41988146-2B47D43C-97DA-4D9E-AC59-AC3F9363C025Q42047805-6BE2C4E7-64C0-44D0-A280-536255F29B5DQ42060377-F7474253-C716-46E1-99FC-C64ACE671EA8Q42098613-673EE76D-C1C7-4D04-BEE9-F6C8F43E2733Q42128455-3967DB21-6A54-4823-BCCB-75DD5D9B4DA3Q42181911-B5A3E738-6CBA-40D2-B324-D20AF8A82E89Q42576400-7950009D-3554-4E65-B4E2-371DA2B90B6FQ42728744-D0B130AE-0756-4E04-99C8-EF484F4EAB7DQ44333618-5B82CDBC-26F7-4D66-9B4F-64FFB6C6E667Q44877360-8FE96C4D-2547-441F-8193-B197C049E42EQ45331211-26041614-8148-4EB3-B8ED-DA7E3C3C12ADQ45892584-F2B526C5-B5CF-433F-8E09-3EED178FD114Q46079361-776D0096-AD0E-4179-89FB-C793999C0931Q46476748-7B238F09-FAAD-42A6-B1AD-B53F80D5B7C7Q47327036-7F35051C-8172-4203-B028-265EBD070C60Q47332697-3C512823-DFB4-4E2E-B3FC-77409F49C318Q47690802-E1464338-4419-439E-8034-95BBAAE6D761
P2860
Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@ast
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@en
type
label
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@ast
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@en
prefLabel
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@ast
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@en
P2093
P1476
Optimizing drug delivery syste ...... " Part I: fundamental aspects.
@en
P2093
Bhupinder Singh
Naveen Ahuja
Rajiv Kumar
P304
P356
10.1615/CRITREVTHERDRUGCARRIERSYST.V22.I1.20
P577
2005-01-01T00:00:00Z